This company listing is no longer active
ECX Stock Overview
Does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Epigenomics AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.70 |
| 52 Week High | €4.50 |
| 52 Week Low | €0.52 |
| Beta | 1.12 |
| 1 Month Change | -54.55% |
| 3 Month Change | -56.25% |
| 1 Year Change | -82.50% |
| 3 Year Change | -97.20% |
| 5 Year Change | -99.76% |
| Change since IPO | -99.88% |
Recent News & Updates
Shareholder Returns
| ECX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | -0.3% |
| 1Y | -82.5% | -14.3% | 7.0% |
Return vs Industry: ECX underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: ECX underperformed the German Market which returned 3.3% over the past year.
Price Volatility
| ECX volatility | |
|---|---|
| ECX Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ECX's share price has been volatile over the past 3 months.
Volatility Over Time: ECX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 18 | Noel Doheny | www.epigenomics.com |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.
Epigenomics AG Fundamentals Summary
| ECX fundamental statistics | |
|---|---|
| Market cap | €616.00k |
| Earnings (TTM) | -€4.46m |
| Revenue (TTM) | €339.23k |
1.8x
P/S Ratio-0.1x
P/E RatioIs ECX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ECX income statement (TTM) | |
|---|---|
| Revenue | €339.23k |
| Cost of Revenue | €56.91k |
| Gross Profit | €282.32k |
| Other Expenses | €4.75m |
| Earnings | -€4.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | -5.07 |
| Gross Margin | 83.22% |
| Net Profit Margin | -1,315.79% |
| Debt/Equity Ratio | -148.3% |
How did ECX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/10 04:00 |
| End of Day Share Price | 2024/07/10 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Epigenomics AG is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bjorn Bostrom | Edison Investment Research |
| Marietta Miemietz | equinet Bank AG (ESN) |
| Simon Scholes | First Berlin Equity Research GmbH |